---
title: "CABA.US (CABA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CABA.US/news.md"
symbol: "CABA.US"
name: "CABA.US"
parent: "https://longbridge.com/en/quote/CABA.US.md"
datetime: "2026-05-19T22:44:17.671Z"
locales:
  - [en](https://longbridge.com/en/quote/CABA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CABA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CABA.US/news.md)
---

# CABA.US (CABA.US) — Related News

### [Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts](https://longbridge.com/en/news/286456613.md)
*2026-05-14T19:15:16.000Z*
> William Blair analyst Sami Corwin has reiterated a Buy rating on Cabaletta Bio (CABA) due to strong non-preconditioned p

### [Cabaletta Bio | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286405197.md)
*2026-05-14T11:10:28.000Z*
### [Cabaletta Bio | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286404901.md)
*2026-05-14T11:08:15.000Z*
### [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | CABA Stock News](https://longbridge.com/en/news/286404329.md)
*2026-05-14T03:05:31.000Z*
> Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | CABA Stock News

### [](https://longbridge.com/en/news/285446480.md)
*2026-05-06T21:54:29.000Z*
> The Nasdaq Biotechnology Index rose more than 2.1%. Among its constituents, Pyxis Oncology surged 25.68%, Veracyte climb

### [U.S. stock night market fluctuations: Cabaletta Bio rose 7.57% in the night market, boosted by a combination of $150 million financing and positive clinical data, driving the stock price surge](https://longbridge.com/en/news/285167723.md)
*2026-05-05T07:36:37.000Z*
> Cabaletta Bio rose 7.57% in the after-hours market; BeiGene fell 1.69% in the after-hours market, with a transaction vol

### [Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed](https://longbridge.com/en/news/285141396.md)
*2026-05-05T01:35:19.000Z*
> Michael Ulz from Morgan Stanley has maintained a Buy rating on Cabaletta Bio with a price target of $13. The rating is s

### [12 Health Care Stocks Moving In Monday's Intraday Session](https://longbridge.com/en/news/285102787.md)
*2026-05-04T17:06:15.000Z*
> CNS Pharmaceuticals (CNSP) shares surged 294.6% to $9.12, while Mobile-health Network (MNDR) rose 63.15% to $1.55. Rally